Table 4.

Univariate and multivariate Cox regression analysis of OS in AHSCT recipients.

Variable		Univariate				Multivariate
		HR	95% CI Lower	95% CI Upper	P value	HR	95% CI Lower	95% CI Upper	P value
Age >60 years		2.55	0.72	8.98	0.1463
Cytogenetic risk group	Standard	Reference
	Unknown	0.48	0.12	1.86	0.3236
	High Risk	0.90	0.09	8.83	0.8003
Sex	F	1.40	0.50	3.88	0.5192
Melphalan dose	Mel 200	Reference
	Reduced dose	0.60	0.12	2.93	0.5303
ISS	I/II	Reference				Reference
	III	1.30	0.47	3.56	0.6151	0.28	0.05	1.77	0.1764
LCD		1.99	0.55	7.18	0.2956
Calcium > 2.75 mmol/L at diagnosis		1.81	0.45	7.21	0.4024
Creatinine > 2 mg/dL at diagnosis		0.59	0.13	2.77	0.5051
HGB< 10 at diagnosis		0.13	0.01	1.28	0.0808	0.04	0.00	1.15	0.0606
Bone disease at diagnosis		0.92	0.28	2.99	0.8876
Induction regimen	Bortezomib-based	0.47	0.15	1.51	0.2069
≥2 lines before AHSCT		2.06	0.72	5.84	0.1762
Maintenance treatment		1.70	0.48	6.08	0.4120
CR before AHSCT		0.74	0.09	5.99	0.7817
CR after AHSCT		0.15	0.02	1.12	0.0649	0.71	0.08	6.76	0.7695
hsa-miR-221-3p T1		0.57	0.22	1.42	0.2262
hsa-miR-15b-5p T1		1.05	0.55	2.00	0.8775
hsa-miR-223-3p T1		0.37	0.14	0.97	0.0432	0.06	0.00	0.99	0.0488
hsa-miR-320c T1		1.37	0.55	3.44	0.5039
hsa-miR-361-3p T1		0.59	0.21	1.61	0.3008
hsa-miR-150-5p T1		1.22	0.57	2.64	0.6049
hsa-miR-221-3p T2		0.37	0.13	1.07	0.0667
hsa-miR-15b-5p T2		0.47	0.22	1.00	0.0493	2.06	0.49	8.61	0.3223
hsa-miR-223-3p T2		0.57	0.31	1.06	0.0759
hsa-miR-320c T2		1.98	1.04	3.74	0.0362	1.09	0.50	2.38	0.8190
hsa-miR-361-3p T2		1.02	0.69	1.52	0.9222
hsa-miR-150-5p T2		0.99	0.54	1.82	0.9828